A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33753733.
- Also identified by DOI 10.1038/s41467-021-22102-6 and PMC identifier 7985487.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Better diagnostic tools are needed to combat the ongoing COVID-19 pandemic. Here, to meet this urgent demand, we report a homogeneous immunoassay to detect IgG antibodies against SARS-CoV-2. This serological assay, called SATiN, is based on a tri-part Nanoluciferase (tNLuc) approach, in which the spike protein of SARS-CoV-2 and protein G, fused respectively to two different tNLuc tags, are used as antibody probes. Target engagement of the probes allows reconstitution of a functional luciferase in the presence of the third tNLuc component. The assay is performed directly in the liquid phase of patient sera and enables rapid, quantitative and low-cost detection. We show that SATiN has a similar sensitivity to ELISA, and its readouts are consistent with various neutralizing antibody assays. This proof-of-principle study suggests potential applications in diagnostics, as well as disease and vaccination management.
Medical subject headings
- Antibodies, Viral
- COVID-19
- COVID-19 Testing
- Immunoassay
- Luciferases
- SARS-CoV-2